Source: VAERS.HHS.GOV
VAERS accepts reports of adverse events and reactions that occur following vaccination. Healthcare providers, vaccine manufacturers, and the public can submit reports to the system. While very important in monitoring vaccine safety, VAERS reports alone cannot be used to determine if a vaccine caused or contributed to an adverse event or illness. The reports may contain information that is incomplete, inaccurate, coincidental, or unverifiable. In large part, reports to VAERS are voluntary, which means they are subject to biases. This creates specific limitations on how the data can be used scientifically. Data from VAERS reports should always be interpreted with these limitations in mind.
The strengths of VAERS are that it is national in scope and can quickly provide an early warning of a safety problem with a vaccine. As part of CDC and FDA’s multi-system approach to post-licensure vaccine safety monitoring, VAERS is designed to rapidly detect unusual or unexpected patterns of adverse events, also known as “safety signals.” If a safety signal is found in VAERS, further studies can be done in safety systems such as the CDC’s Vaccine Safety Datalink (VSD) or the Clinical Immunization Safety Assessment (CISA) project. These systems do not have the same scientific limitations as VAERS, and can better assess health risks and possible connections between adverse events and a vaccine.
Key considerations and limitations of VAERS data:
VAERS data available to the public include only the initial report data to VAERS. Updated data which contains data from medical records and corrections reported during follow up are used by the government for analysis. However, for numerous reasons including data consistency, these amended data are not available to the public.
93 yo M hx of HLD HTN RBBB presenting with weakness and feeling dehydrated. Patient had received covid-19 shot and was unable to walk to his car (200 ft), because he was weak. Asked another patient for help and they alerted staff, who wheeled him to the ED. Patient initially declining any intervention, not in pain, or mental confusion. Vital signs mostly normal, elevated heart rate, ran ekg and tropinin Patient Sent to cardiac unit at local Hospital then transferred to another HCF for stent
Open in Wayback Machine
(If this is a foreign report without a description you will be able to read the description in the Wayback Machine on Medalerts if the report became public for the first time before November 18, 2022.)
| Name | Dose # | Type | Manufacturer | Lot | Route | Site |
|---|---|---|---|---|---|---|
| COVID19 (COVID19 (PFIZER-BIONTECH)) | 3 | COVID19 | PFIZER\BIONTECH | FF8841 | SYR | LA |
| RECVDATE: | 10-15-2021 | RPT_DATE: |
| CAGE_YR: | 93 |
| CAGE_MO: | |
| DIED: | U |
| DATEDIED: | |
| L_THREAT: | Y |
| ER_VISIT: | |
| HOSPITAL: | Y |
| HOSPDAYS: | 5 |
| X_STAY: | U |
| DISABLE: | U |
| RECOVD: | U |
| LAB_DATA: | Troponin I 0.77 (H) - 0.00 - 0.04 ng/mL Platelets count 95 (L) 140 - 400 K/uL ECG elevated ecg was done - elevated RBBBB on II III AVF HEART |
| V_ADMINBY: | PVT |
| OTHER_MEDS: | LisinoprilaL Alvesco Lorzolimide Lumican Vitamin C, D, Zinc |
| CUR_ILL: | |
| HISTORY: | CHRONIC BRONCHITIS HYPERLIPIDEMIA HTN (HYPERTENSION) PREDIABETES THORACIC AORTIC ANEURYSM RIGHT BUNDLE BRANCH BLOCK BPH (BENIGN PROSTATIC HYPERTROPHY) ATHEROSCLEROSIS OF AORTA ALCOHOL PREVENTION COUNSELING RIGHT PSEUDOEXFOLIATION GLAUCOMA, SEVERE STAGE CKD STAGE 3B (GFR 30-44) LEUKOPENIA THROMBOCYTOPENIA, UNSPECIFIED |
| PRIOR_VAX: | |
| SPLTTYPE: | |
| FORM_VERS: | |
| TODAYS_DATE: | 10-15-2021 |
| BIRTH_DEFECT: | U |
| OFC_VISIT: | U |
| ER_ED_VISIT: | U |
| ALLERGIES: | |
| V_FUNDBY: |
Questions? Comments? Bugs?
[email protected]
Due to the high volume of inquiries, please be patient with response times.
AND PLEASE read the FAQ first.
OpenVAERS is a private organization that posts publicly available CDC/FDA data of injuries reported post-vaccination. Reports are not proof of causality.